228 related articles for article (PubMed ID: 29588307)
21. Oncogenic FGFR3 gene fusions in bladder cancer.
Williams SV; Hurst CD; Knowles MA
Hum Mol Genet; 2013 Feb; 22(4):795-803. PubMed ID: 23175443
[TBL] [Abstract][Full Text] [Related]
22. FGFR3-TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle.
Sarkar S; Ryan EL; Royle SJ
Open Biol; 2017 Aug; 7(8):. PubMed ID: 28855393
[TBL] [Abstract][Full Text] [Related]
23. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
[TBL] [Abstract][Full Text] [Related]
24. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas.
McDonald MF; Athukuri P; Anand A; Gopakumar S; Jalali A; Patel AJ; Rao G; Goodman JC; Lu HC; Mandel JJ
Neurosurg Focus; 2022 Dec; 53(6):E16. PubMed ID: 36455273
[TBL] [Abstract][Full Text] [Related]
25. Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs.
Georgescu MM; Islam MZ; Li Y; Traylor J; Nanda A
Acta Neuropathol Commun; 2021 Apr; 9(1):69. PubMed ID: 33853673
[TBL] [Abstract][Full Text] [Related]
26. FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients.
Wang Z; Zhang C; Sun L; Liang J; Liu X; Li G; Yao K; Zhang W; Jiang T
Oncotarget; 2016 Dec; 7(51):84587-84593. PubMed ID: 27829236
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability.
Wang CG; Peiris MN; Meyer AN; Nelson KN; Donoghue DJ
Oncotarget; 2023 Feb; 14():133-145. PubMed ID: 36780330
[TBL] [Abstract][Full Text] [Related]
28. FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium.
Best SA; Harapas CR; Kersbergen A; Rathi V; Asselin-Labat ML; Sutherland KD
Oncogene; 2018 Nov; 37(46):6096-6104. PubMed ID: 29991799
[TBL] [Abstract][Full Text] [Related]
29. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
30. Successful Treatment and Retreatment With Erdafitinib for a Patient With
Pham C; Lang D; Iams WT
JTO Clin Res Rep; 2023 May; 4(5):100511. PubMed ID: 37214414
[No Abstract] [Full Text] [Related]
31. Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives.
Picca A; Sansone G; Santonocito OS; Mazzanti CM; Sanson M; Di Stefano AL
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067258
[TBL] [Abstract][Full Text] [Related]
32. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
33. Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma.
Wu Y; Jin W; Wang Q; Zhou J; Wang Y; Tan Y; Cui X; Tong F; Yang E; Wang J; Kang C
Mol Ther; 2021 Nov; 29(11):3305-3318. PubMed ID: 34274537
[TBL] [Abstract][Full Text] [Related]
34. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
35. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Lassman AB; Sepúlveda-Sánchez JM; Cloughesy TF; Gil-Gil MJ; Puduvalli VK; Raizer JJ; De Vos FYF; Wen PY; Butowski NA; Clement PMJ; Groves MD; Belda-Iniesta C; Giglio P; Soifer HS; Rowsey S; Xu C; Avogadri F; Wei G; Moran S; Roth P
Clin Cancer Res; 2022 Jun; 28(11):2270-2277. PubMed ID: 35344029
[TBL] [Abstract][Full Text] [Related]
36. Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma.
Dewaele B; Przybyl J; Quattrone A; Finalet Ferreiro J; Vanspauwen V; Geerdens E; Gianfelici V; Kalender Z; Wozniak A; Moerman P; Sciot R; Croce S; Amant F; Vandenberghe P; Cools J; Debiec-Rychter M
Int J Cancer; 2014 Mar; 134(5):1112-22. PubMed ID: 23959973
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.
Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA
Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666
[TBL] [Abstract][Full Text] [Related]
38. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.
Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
[TBL] [Abstract][Full Text] [Related]
39. A metabolic function of FGFR3-TACC3 gene fusions in cancer.
Frattini V; Pagnotta SM; Tala ; Fan JJ; Russo MV; Lee SB; Garofano L; Zhang J; Shi P; Lewis G; Sanson H; Frederick V; Castano AM; Cerulo L; Rolland DCM; Mall R; Mokhtari K; Elenitoba-Johnson KSJ; Sanson M; Huang X; Ceccarelli M; Lasorella A; Iavarone A
Nature; 2018 Jan; 553(7687):222-227. PubMed ID: 29323298
[TBL] [Abstract][Full Text] [Related]
40. Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
Bou Zerdan M; Bratslavsky G; Jacob J; Ross J; Huang R; Basnet A
Mol Diagn Ther; 2023 Jul; 27(4):475-485. PubMed ID: 37195586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
